Last reviewed · How we verify
NCT06157450
Pharmacokinetics of ZSP1273 in Elder Participants
Phase 1 trial testing ZSP1273 in Elder in 32 participants. Completed in 17 November 2023.
1 November 2023
Quick facts
| Lead sponsor | Guangdong Raynovent Biotech Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 32 |
| Start date | 11 October 2023 |
| Primary completion | 1 November 2023 |
| Estimated completion | 17 November 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- ZSP1273 — full drug profile →
Conditions studied
- Elder — all drugs for Elder →
Sponsor
Guangdong Raynovent Biotech Co., Ltd — full company profile →
Who can join
18 and older, any sex, with Elder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety, tolerability and PK of ZSP1273 in elder Participants
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06157450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ZSP1273
Trials testing the same drug.
- NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07229820 — Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT06248567 — Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease · Phase 1 · completed
- NCT05954624 — Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid · Phase 1 · completed
- NCT05942365 — A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam · Phase 1 · completed
Other Guangdong Raynovent Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07460284 — A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants · Phase 1 · not yet recruiting
- NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07229820 — Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07139535 — A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone · Phase 3 · not yet recruiting
- NCT07139548 — A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06157450 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Raynovent Biotech Co., Ltd
- Last refreshed: 5 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06157450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing